| Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways L Kraehenbuehl, CH Weng, S Eghbali, JD Wolchok, T Merghoub Nature reviews Clinical oncology 19 (1), 37-50, 2022 | 434 | 2022 |
| Dermatophyte identification in skin and hair samples using a simple and reliable nested polymerase chain reaction assay J Verrier, L Krähenbühl, O Bontems, M Fratti, K Salamin, M Monod British Journal of Dermatology 168 (2), 295-301, 2013 | 69 | 2013 |
| T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants D Hirschhorn, S Budhu, L Kraehenbuehl, M Gigoux, D Schröder, A Chow, ... Cell 186 (7), 1432-1447. e17, 2023 | 64 | 2023 |
| European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position … Z Apalla, V Nikolaou, D Fattore, G Fabbrocini, A Freites‐Martinez, ... Journal of the European Academy of Dermatology and Venereology 36 (3), 332-350, 2022 | 43 | 2022 |
| Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy E Goleva, T Lyubchenko, L Kraehenbuehl, ME Lacouture, DYM Leung, ... Annals of Allergy, Asthma & Immunology 126 (6), 630-638, 2021 | 33 | 2021 |
| A longitudinal analysis of IDO and PDL1 expression during immune-or targeted therapy in advanced melanoma L Krähenbühl, SM Goldinger, J Mangana, K Kerl, I Chevolet, L Brochez, ... Neoplasia 20 (2), 218-225, 2018 | 33 | 2018 |
| In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response A Sahu, K Kose, L Kraehenbuehl, C Byers, A Holland, T Tembo, ... Nature Communications 13 (1), 5312, 2022 | 25 | 2022 |
| Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab C Brüggemann, MC Kirchberger, SM Goldinger, B Weide, A Konrad, ... Journal of cancer research and clinical oncology 143, 1977-1984, 2017 | 16 | 2017 |
| Immune-related cutaneous adverse events due to checkpoint inhibitors E Wang, L Kraehenbuehl, K Ketosugbo, JA Kern, ME Lacouture, ... Annals of Allergy, Asthma & Immunology 126 (6), 613-622, 2021 | 15 | 2021 |
| Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide A Pan, RE Reingold, JL Zhao, A Moy, L Kraehenbuehl, G Dranitsaris, ... The Journal of urology 207 (5), 1010-1019, 2022 | 14 | 2022 |
| Pilot trial of arginine deprivation plus nivolumab and ipilimumab in patients with metastatic uveal melanoma L Kraehenbuehl, A Holland, E Armstrong, S O’Shea, L Mangarin, ... Cancers 14 (11), 2638, 2022 | 13 | 2022 |
| Management of immune-related cutaneous adverse events with dupilumab AMS Kuo, S Gu, J Stoll, AP Moy, SW Dusza, A Gordon, EC Haliasos, ... Journal for Immunotherapy of Cancer 11 (6), 2023 | 7 | 2023 |
| Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement AM Kuo, L Kraehenbuehl, S King, DYM Leung, E Goleva, AP Moy, ... Cancers 14 (12), 2995, 2022 | 4 | 2022 |
| Oral minoxidil for the treatment of late alopecia in cancer survivors. AMS Kuo, RE Reingold, K Ketosugbo, A Pan, SW Dusza, L Kraehenbuehl, ... Journal of Clinical Oncology 40 (16_suppl), 12022-12022, 2022 | 4 | 2022 |
| Histiocytosis in the dermatological context of the new classification C Lang, JT Maul, L Krähenbühl, F Dimitriou, R Dummer Der Hautarzt 70, 691-699, 2019 | 2 | 2019 |
| Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. C Brueggemann, B Weide, SM Goldinger, A Konrad, M Erdmann, ... Journal of Clinical Oncology 33 (15_suppl), 9044-9044, 2015 | 2 | 2015 |
| Effect of immune checkpoint inhibitors on asthma EA Wang, E Goleva, K Ketosugbo, JA Kern, L Kraehenbuehl, ... Annals of allergy, asthma & immunology: official publication of the American …, 2022 | 1 | 2022 |
| Checkpoint inhibition induced pruritus during cancer therapy is associated with skin IL-31 and CCL22 expression E Wang, T Lyubchenko, E Goleva, L Kraehenbuehl, K Ketosugbo, A Moy, ... Journal of Allergy and Clinical Immunology 149 (2), AB173, 2022 | 1 | 2022 |
| Histiozytäre Neoplasien im Kontext der aktuellen Klassifikation C Lang, JT Maul, L Krähenbühl, F Dimitriou, R Dummer Der Hautarzt 70 (9), 691-699, 2019 | 1 | 2019 |
| Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways ME Lacouture, E Goleva, N Shah, V Rotemberg, L Kraehenbuehl, ... Clinical Cancer Research, 2024 | | 2024 |
